Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/38980
Title: Next generation sequencing of circulating cell-free DNA evaluating mutations and gene amplification in metastatic breast cancer
Authors: Page, Karen
Guttery, David S.
Fernadez-Garcia, Daniel
Hills, A.
Hastings, Robert K.
Luo, Jinli
Goddard, K.
Shahin, V.
Woodley-Barker, L.
Rosales, B. M.
Coombes, R. C.
Stebbing, J.
Shaw, Jacqueline A.
First Published: 9-Dec-2016
Publisher: American Association for Clinical Chemistry
Citation: Clinical Chemistry 63:2
Abstract: Background: Breast cancer tissues are heterogeneous and show diverse somatic mutations and somatic copy number alterations (CNAs). We used a novel targeted next generation sequencing (NGS) panel to examine cell-free DNA (cfDNA) to detect somatic mutations and gene amplification in women with metastatic breast cancer (MBC). Methods: cfDNA from pretreated patients (n = 42) and 9 healthy controls were compared with matched lymphocyte DNA by NGS, using a custom 158 amplicon panel covering hot-spot mutations and CNAs in 16 genes, with further validation of results by droplet digital PCR. Results: No mutations were identified in cfDNA of healthy controls, whereas exactly half the patients with metastatic breast cancer had at least one mutation or amplification in cfDNA (mean 2, range 1–6) across a total of 13 genes. Longitudinal follow up showed dynamic changes to mutations and gene amplification in cfDNA indicating clonal and subclonal response to treatment that was more dynamic than cancer antigen 15-3 (CA15-3). Interestingly, at the time of blood sampling disease progression was occurring in 7 patients with erb-b2 receptor tyrosine kinase 2 (ERBB2) gene amplification in their cfDNA and 3 of these patients were human epidermal growth factor receptor 2 (HER2) negative at diagnosis, suggesting clonal evolution to a more aggressive phenotype. Lastly, 6 patients harbored estrogen receptor 1 (ESR1) mutations in cfDNA, suggesting resistance to endocrine therapy. Overall 9 of 42 patients (21%) had alterations in cfDNA that could herald a change in treatment. Conclusions: Targeted NGS of cfDNA has potential for monitoring response to targeted therapies through both mutations and gene amplification, for analysis of dynamic tumor heterogeneity and stratification to targeted therapy.
DOI Link: 10.1373/clinchem.2016.261834
ISSN: 0009-9147
eISSN: 1530-8561
Links: http://clinchem.aaccjnls.org/content/early/2016/12/09/clinchem.2016.261834
http://hdl.handle.net/2381/38980
Embargo on file until: 9-Dec-2017
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Creative Commons “Attribution Non-Commercial No Derivatives” licence CC BY-NC-ND, further details of which can be found via the following link: http://creativecommons.org/licenses/by-nc-nd/4.0/ Archived with reference to SHERPA/RoMEO and publisher website.
Description: Previously published online at DOI: 10.1373/clinchem.2016.261834 12 Month Embargo on this manuscript.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
clinchem.2016.261834.full.pdfPublisher version2.37 MBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.